| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac46d7f02c90685224d593dfa1552803 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0012
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2018-10-10^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a404814fb72ed84f505d01992ab2d1cd |
| publicationDate |
2019-04-18^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019073299-A1 |
| titleOfInvention |
IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS |
| abstract |
The present invention provides methods for treating a central nervous system (CNS) tumor in a subject comprising administering an IL-4-targeting cargo protein formulated in an artificial cerebrospinal fluid formulation. The present invention also relates to formulations and methods of administration together with an auxiliary tracer for monitoring. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020160639-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022077102-A1 |
| priorityDate |
2017-10-10^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |